In Health Care's "New Normal," Value Will Be King
This article was originally published in The Gray Sheet
Executive SummaryCovidien executive Liesl Cooper says new government policies demand that manufacturers rethink the value of their technology going forward.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.